Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-63P is a non-coding RNA gene annotated as a pseudogene corresponding to the U4 small nuclear RNA family, which normally plays a role as an RNA component of the major spliceosome. However, as a pseudogene, RNU4-63P does not encode a functional small nuclear RNA and is not known to have a biological role or disease association[1][5][7]. RNU4-63P is not a protein, enzyme, receptor, or other canonical drug target; it is listed as a pseudogene—meaning it does not produce a functional product[1][7]. There is no evidence for any biological or clinical function, nor established roles in disease, biomarkers, or known drug interactions for this specific pseudogene[1][7][6]. Pseudogenes like RNU4-63P are typically non-functional copies of genes and rarely serve as therapeutic targets. It is important not to confuse RNU4-63P with functional U4 snRNA genes (such as RNU4-2), which are known to play roles in RNA splicing and may be implicated in neurodevelopmental disorders, but RNU4-63P is not among these functional variants[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 63, pseudogene (RNU4-63P).